Molecular and Antigenic Properties of Mammalian Cell-Expressed Theileria parva Antigen Tp9

This study was carried out in accordance with the recommendations of The U.S. Animal Welfare Act (United States Code, Title 7, Chapter 54, sections 2131–2159) and Animal Welfare Regulations (Code of Federal Regulations, Title 9, Chapter 1, Subchapter A, parts 1–4). The protocol was approved by the Washington State University Institutional Animal Care and Use Committee, protocol number 4980. Therapeutic drugs were administered according to the manufacturer's dosing instructions. Six MHC class I A10 or A14 haplotype-matched (27) Holstein-Friesian steer calves obtained at 3–6 months of age were utilized in this study. Pre-infection complete blood counts (CBCs) were normal, and all calves tested negative on a pre-infection T. parva PIM enzyme-linked immunosorbent assay (ELISA) as previously described (28). Four steers (#139, #147, #152, and #158) were infected with a T. parva Muguga stabilate and concomitantly treated with oxytetracycline as previously described (29). Beginning 3 days after ITM, the temperature, pulse, respiratory rate, and CBC were monitored daily for each animal. Steers that developed significant pyrexia (rectal temperature >40.2°C) were treated with flunixin meglumine, and those that developed dyspnea were treated with furosemide and buparvaquone. Animals were re-infected three more times at 6 month intervals, and were monitored for adverse reactions as above for each infection; ho...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research